140 related articles for article (PubMed ID: 32496458)
1. Diagnosis, Risk Stratification, and Treatment of Peripheral T-Cell Lymphomas: Past and Present.
Pearse WB; Pro B
Cancer J; 2020; 26(3):253-259. PubMed ID: 32496458
[TBL] [Abstract][Full Text] [Related]
2. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG; Byrd JC; Abramson JS; Bilgrami SF; Bociek G; Brander D; Brown J; Chanan-Khan AA; Chavez JC; Coutre SE; Davis RS; Fletcher CD; Hill B; Kahl BS; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Lim MS; Ma S; Malek S; Mato A; Mosse C; Shadman M; Siddiqi T; Stephens D; Sundaram S; Wagner N; Dwyer M; Sundar H
J Natl Compr Canc Netw; 2020 Feb; 18(2):185-217. PubMed ID: 32023533
[TBL] [Abstract][Full Text] [Related]
3. Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.
Rodríguez J; Gutiérrez A; Martínez-Delgado B; Perez-Manga G
Crit Rev Oncol Hematol; 2009 Sep; 71(3):181-98. PubMed ID: 19056295
[TBL] [Abstract][Full Text] [Related]
4. Advances in Treatment of Follicular Lymphoma.
Luminari S; Trotman J; Federico M
Cancer J; 2020; 26(3):231-240. PubMed ID: 32496456
[TBL] [Abstract][Full Text] [Related]
5. How to select the frontline treatment for a patient with peripheral T-cell lymphoma.
Ansell S
Leuk Lymphoma; 2016; 57(4):783-8. PubMed ID: 26850659
[TBL] [Abstract][Full Text] [Related]
6. [Peripheral T cell lymphomas: diagnosis and treatment].
Galtier J; Parrens M; Milpied N
Rev Med Interne; 2020 Dec; 41(12):829-837. PubMed ID: 32674892
[TBL] [Abstract][Full Text] [Related]
7. Immune and Cell Therapy in Non-Hodgkin Lymphoma.
Merryman RW; Houot R; Armand P; Jacobson C
Cancer J; 2020; 26(3):269-277. PubMed ID: 32496460
[TBL] [Abstract][Full Text] [Related]
8. The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naΪve patients with peripheral T-cell lymphoma: a systematic review of the literature.
Jethwa KD; Bishton MJ; Fox CP
Br J Haematol; 2017 Aug; 178(3):476-479. PubMed ID: 27146257
[No Abstract] [Full Text] [Related]
9. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.
Chang EWY; Tan YH; Chan JY
J Hematol Oncol; 2024 Jun; 17(1):38. PubMed ID: 38824603
[TBL] [Abstract][Full Text] [Related]
10. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
[TBL] [Abstract][Full Text] [Related]
11. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
12. Improving therapy for patients with aggressive lymphoma.
Armitage JO
Transfus Apher Sci; 2011 Apr; 44(2):179-82. PubMed ID: 21345733
[TBL] [Abstract][Full Text] [Related]
13. Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell Lymphoma.
Hidalgo Lopez JE; Yabe M; Carballo-Zarate AA; Wang SA; Jorgensen JL; Ahmed S; Lee J; Li S; Schlette E; McDonnell T; Miranda RN; Medeiros LJ; Bueso-Ramos CE; Yin CC
J Natl Compr Canc Netw; 2016 Aug; 14(8):939-44. PubMed ID: 27496109
[TBL] [Abstract][Full Text] [Related]
14. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
15. Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?
Macapagal SC; Bennani NN
Blood Rev; 2023 Jul; 60():101071. PubMed ID: 36898933
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic advancements in peripheral T-cell lymphoma.
Reddy NM; Evens AM
Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
[TBL] [Abstract][Full Text] [Related]
17. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Brown P; Inaba H; Annesley C; Beck J; Colace S; Dallas M; DeSantes K; Kelly K; Kitko C; Lacayo N; Larrier N; Maese L; Mahadeo K; Nanda R; Nardi V; Rodriguez V; Rossoff J; Schuettpelz L; Silverman L; Sun J; Sun W; Teachey D; Wong V; Yanik G; Johnson-Chilla A; Ogba N
J Natl Compr Canc Netw; 2020 Jan; 18(1):81-112. PubMed ID: 31910389
[TBL] [Abstract][Full Text] [Related]
18. Zebras and hen's teeth: recognition and management of rare T and NK lymphomas.
Mehta-Shah N; Horwitz S
Hematology Am Soc Hematol Educ Program; 2015; 2015():545-9. PubMed ID: 26637770
[TBL] [Abstract][Full Text] [Related]
19. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.
Cui L; Liu Y; Pang Y; Qian T; Quan L; Cheng Z; Dai Y; Ye X; Pang Y; Shi J; Ke X; Wu D; Fu L
Cancer Gene Ther; 2020 Feb; 27(1-2):1-14. PubMed ID: 31292516
[TBL] [Abstract][Full Text] [Related]
20. The role of high-dose therapy in peripheral T-cell lymphomas.
Reimer P; Rüdiger T; Wilhelm M
Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
